| Compound | Sponsor | Target | Cancer type | Stage |
| Vitaxin/etaracizumab | MedImmune Inc., NCI | v3 | Solid tumors, melanoma, colorectal cancer, small intestine cancer, lymphoma, prostate cancer, and renal cell cancer | Phase I, II | CTNO 95 | Centocor Inc. | v integrins | Solid tumors, melanoma, and prostate cancer | Phase I, II | Cilengitide (cyclic RGD) | EMD Pharmaceuticals, Merck | v3, v5 | Lung cancer, prostate cancer, melanoma, glioblastoma, leukemia, brain and CNS tumors, breast cancer, and squamous cell cancer | Phase I, II | Volociximab | Protein Design Labs | 51 | Solid tumors, melanoma, ovarian cancer, renal cancer, pancreatic cancer, and lung cancer | Phase I, II | ATN-161 PHSRN mimetic | Attenuon | 51 and other fibronectin-binding integrins | Solid tumors, renal cell carcinoma, and brain and CNS tumors | Phase I | PF-00562271 | Verastem Inc. | FAK, Pyk2 | Head and neck cancer, prostate cancer, and pancreatic cancer | Phase I | GSK2256098 | GlaxoSmithKline | FAK, Pyk2 | Solid tumors | Phase I | PF-04554878 | Verastem Inc. | FAK, Pyk2 | Metastatic, nonhematologic tumors | Phase I | VS-4718 | Verastem Inc. | FAK, Pyk2 | Metastatic, nonhematologic tumors | Phase I | VS-6063 | Verastem Inc. | FAK, Pyk2 | Ovarian cancer | Phase I |
|
|